Back to results
CompletedPhase 2

Solanezumab Safety Study in Japanese Patients With Alzheimer's Disease

NCT00749216

What is this trial?

Generating plain-language summary...

Am I eligible?

Generating eligibility summary...

What's involved?

Summarizing study design...

Where and how to apply

Primary location

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Ehime, Japan

+5 additional locations

View on ClinicalTrials.gov
Solanezumab Safety Study in Japanese Patients With Alzheimer's Disease — TrialFind